All In Biotech

Drug Trial Radar · NCT01030783

A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma (TIVO-1)

Last checked: Nov 19, 2026Latest source record: Oct 28, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 517 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

517

Actual

Start

Dec 2009

Primary completion

Jul 2012

Study completion Jun 2013

Sponsor

Lead sponsor
AVEO Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Dec 11, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, randomized, controlled, multi-national, multi-center, parallel-arm trial comparing tivozanib to sorafenib in subjects with advanced RCC. The study is designed to compare the PFS, OS, ORR, DR, safety and tolerability, and kidney specific symptoms/health outcome measurements of tivozanib and sorafenib.

Conditions

  • Advanced Renal Cell Carcinoma

Interventions

  • tivozanib (AV-951)Drug

    Tivozanib: 1.5 mg orally once daily. Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.

  • SorafenibDrug

    Sorafenib: 400 mg orally twice daily. Subjects will receive 400 mg (2 x 200 mg tablets) sorafenib twice daily continuously, beginning on Day 1. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS) of Subjects With Advanced Renal Cell Cancer (RCC) Randomized to Treatment With Tivozanib or SorafenibTime frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first. Disease progression was assessed every 8 weeks.

Locations

86 sites in 16 countries. Site status is shown where the registry gives one.

  • Site 185

    Los Angeles, California

  • Site 180

    Gainesville, Florida

  • Site 184

    Orlando, Florida

  • Site 182

    Minneapolis, Minnesota

  • Site 186

    New York, New York

  • Site 187

    Dallas, Texas

  • Site 102

    Sante Fe, Argentina

  • Site 403

    Plovdiv, Bulgaria

  • Site 404

    Sofia, Bulgaria

  • Site 400

    Sofia, Bulgaria

  • Site 401

    Varna, Bulgaria

  • Site 402

    Veliko Tarnovo, Bulgaria

  • Site 110

    Montreal, Quebec, Canada

  • Site 122

    Santiago, Chile

  • Site 123

    Temuco, Chile

  • Site 121

    La Reina, Santiago de Chile, Chile

  • Site 411

    Prague, Czechia

  • Site 130

    Marseille, France

  • Site 133

    Saint-Herblain, France

  • Site 423

    Budapest, Hungary

  • Site 421

    Kaposvár, Hungary

  • Site 422

    Pécs, Hungary

  • Site 424

    Szombathely, Hungary

  • Site 154

    Delhi, India

  • Site 157

    Hyderabad, Andhra Pradesh, India

  • Site 190

    Patna, Bihar, India

  • Site 156

    Ahmedabad, Gujarat, India

  • Site 151

    Nashik, Maharashtra, India

  • Site 153

    Pune, Maharashtra, India

  • Site 159

    Pune, Maharashtra, India

  • Site 191

    Jaipur, Rajasthan, India

  • Site 155

    Jaipur, Rajasthan, India

  • Site 152

    Vellore, Tamil Nadu, India

  • Site 158

    Lucknow, Uttar Pradesh, India

  • Site 150

    Kolkata, West Bengal, India

  • Site 160

    Arezzo, Italy

  • Site 161

    Pavia, Italy

  • Site 162

    Roma, Italy

  • Site 432

    Bialystok, Poland

  • Site 434

    Bydgoszcz, Poland

Showing 40 of 86 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.